rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GNLX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates

      -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung cancer -- -- Olvi-Vec systemic development programs continue to advance in SCLC and NSCLC, with additional dose-escalation updates expected by year-end 2026 -- -- $15.5 million in pro forma cash and inves

      Nov 16Yahoo FinanceGNLX
      Genelux CSO Yu Yong sells $1,343 in company stock
      Nov 5Investing.comGNLX
      Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

      -- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy -- -- Findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness t

      Sep 9Yahoo FinanceGNLX
      12 Health Care Stocks Moving In Friday's After-Market Session
      Sep 4BenzingaGNLXISPC
      Genelux chief scientific officer Yu Yong sells $26,658 of stock
      Sep 3Investing.comGNLX
      Genelux CEO Zindrick sells $91,899 in common stock
      Sep 3Investing.comGNLX
      Genelux CTO Joseph Cappello sells $28,112 in company stock
      Sep 3Investing.comGNLX

      This is the newest page. Registered accounts read further back.